Swiss Exports to the US Jump 43% in September as Pharma Shipments Rise Before Tariffs

Post by : Saif Nasser

Switzerland’s exports to the United States rose sharply in September as pharmaceutical companies increased their shipments ahead of new U.S. tariffs. Official data released on Tuesday showed that exports to the U.S. grew by almost 43% compared to the previous month, marking one of the strongest rebounds in trade between the two countries this year.

The Swiss government said the rise was mainly driven by higher exports of medicines and chemical products. These shipments increased as companies rushed to deliver their goods before new import taxes came into effect in October. Overall, total Swiss exports across all sectors rose 3.4% in September, but the growth was especially strong in trade with the United States.

The spike in exports followed a difficult August when U.S. President Donald Trump announced a 39% tariff on many Swiss goods. The tariffs, which took effect immediately, led to a sharp decline in Swiss exports that month. However, pharmaceutical companies were exempted from the first round of duties, which helped them continue sending products to the U.S. market.

President Trump later said that starting from October 1, the U.S. government would impose a 100% tariff on all branded or patented pharmaceutical imports — unless the companies involved were building manufacturing plants within the United States. The move was part of his broader “America First” trade policy aimed at encouraging companies to produce more goods domestically.

In response, major Swiss drugmakers such as Roche and Novartis said they believed the new tariffs would not affect them because both companies already have large investments and production facilities in the U.S. Roche, one of the world’s largest biotech firms, produces several of its key medicines in American plants. Novartis has also been expanding its research and manufacturing operations in New Jersey and North Carolina.

Government data showed that total exports of chemical and pharmaceutical products from Switzerland increased by 5.1% in September compared to the previous month. These goods account for more than half of Switzerland’s total exports, making the sector a crucial part of the country’s economy.

Trade analysts said the rush to ship products before the tariff deadline explains the sharp rise in export numbers. “Swiss companies wanted to move as much stock as possible to the U.S. before the new tariffs started,” said Zurich-based economist Markus Keller. “Pharmaceuticals are a major part of Swiss exports, so even a small change in this sector has a big impact on overall trade figures.”

The United States remains one of Switzerland’s most important trading partners, especially for high-value goods like medicines, chemicals, watches, and precision instruments. Last year, Swiss exports to the U.S. totaled over $60 billion, led by pharmaceutical sales.

However, the recent tariff announcements have created uncertainty for Swiss businesses. Many exporters fear that future trade restrictions could make it harder to compete in the U.S. market. “The new tariffs are a warning signal,” said Keller. “Even if some big pharmaceutical firms are safe for now, smaller exporters could face higher costs in the coming months.”

The Trump administration has argued that tariffs are necessary to protect American manufacturing and reduce dependence on foreign-made products. But critics say the measures could hurt U.S. consumers by raising prices for imported goods, including vital medicines.

Switzerland’s economy, known for its stability and strong export performance, has so far managed to absorb the impact of global trade tensions. Still, experts warn that if tariffs expand to more products, the long-term effects could slow down Swiss export growth.

Swiss companies have already begun exploring ways to adapt. Some are considering increasing production in the United States to avoid future tariffs, while others are looking for alternative markets in Asia and Europe. “Many companies are trying to reduce their exposure to the U.S. market risk,” said an industry representative. “But the American market is too big to ignore.”

For now, the September trade data offers a short-term boost for Switzerland’s export numbers, but the overall picture remains uncertain. Economists expect that the next few months will show whether the strong performance in September was a one-time event or part of a longer trend.

As the global trade environment remains tense, Switzerland’s export-driven economy may face more challenges ahead. The government has not yet commented on whether it plans to negotiate with the U.S. over the new tariffs, but trade officials have said they are monitoring the situation closely.

Despite the risks, the strong performance of pharmaceutical companies like Roche and Novartis shows the resilience of Switzerland’s economy. Their ability to adapt quickly to new trade conditions has helped protect one of the country’s most valuable industries.